Equitable State Allocation: Promising Practices for Promoting Utilization of COVID-19 Monoclonal Antibody Treatments

Promising Practices mAbs Promotion Nov 2021 Cover

Policy Brief

Equitable State Allocation: Promising Practices for Promoting Utilization of COVID-19 Monoclonal Antibody Treatments

Published date

November 22, 2021

Driven by limited supply of monoclonal antibody (mAb) therapies and sharply rising demand for mAb treatment during the Delta variant-driven spike in cases, the Federal government shifted to facilitating state- and territory-coordinated allocation of mAb therapies. To support state leaders in promoting equitable access to mAb therapies—as well as flexibility in allocation processes amid shifting supply and demand—this issue brief outlines promising approaches for states to address key considerations around data tracking, patient prioritization, distribution logistics, and community engagement.

Duke-Margolis Affiliated Authors

Brian Canter Headshot

Brian Canter, Ph.D.

Senior Policy Analyst

matt d'ambrosio headshot

Matt D'Ambrosio

Research Assistant

Katie Greene

Katie Greene

Assistant Research Director
Senior Team Member

Andrea Thoumi

Andrea Thoumi, MPP, MSc

Health Equity Policy Fellow
Senior Team Member
Anti-Racism and Equity Committee Member
Core Faculty Member
Adjunct Assistant Professor
2020 Intern Mentor

morgan romine

Morgan Romine, MPA

Chief of Staff
Senior Team Member

Mark McClellan

Mark McClellan, MD, PhD

Director of Margolis Center
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty